Rhythm Pharmaceuticals, Inc.
Every calculator, already run for RYTM
Open the full toolkit →You have the numbers on RYTM. Get the argument.
A written report on which of these readings actually decide the outcome for Rhythm Pharmaceuticals, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
19 analysts covering RYTMAnalyst Price Target Disagreement for Rhythm Pharmaceuticals, Inc.
Wall Street's bull case implies +51% from the current price; the bear case implies +13%. A 38% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for RYTM
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency…
RYTM — frequently asked
Is RYTM a buy right now?
Wall Street's consensus rating on Rhythm Pharmaceuticals, Inc. is Strong Buy across 19 analysts, with a mean price target of $140.29 (+32% vs. the current $106.28). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
What is the analyst price target disagreement for Rhythm Pharmaceuticals, Inc.?
Analysts covering Rhythm Pharmaceuticals, Inc. (RYTM) range from a bear-case target of $120.00 to a bull-case high of $160.00, with a mean consensus target of $140.29 across 17 analysts. The spread of $40.00 (38% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Rhythm Pharmaceuticals, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Rhythm Pharmaceuticals, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full RYTM research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Rhythm Pharmaceuticals, Inc., in minutes. 3 free reports included with every account — no credit card required.